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Summary
Recent studies suggest that hereditary prostate cancer
(PRCA) is a complex disease, involving multiple suscep-
tibility genes and variable phenotypic expression.
Through linkage analysis, potential prostate cancer sus-
ceptibility loci have been mapped to 3 regions on chro-
mosome 1. To investigate the reported linkage to these
regions, we conducted linkage studies on 144 PRCA
families by using microsatellite markers in regions 1q24-
25 (HPC1) and 1q42.2-43 (PCAP). We also examined
the 1p36 (CAPB) region in 13 PRCA families with at
least one case of brain cancer. No significant evidence
of linkage to the HPC1 or PCAP region was found when
the entire data set was analyzed. However, weak evi-
dence for linkage to HPC1 was observed in the subset
of families with male-to-male transmission ( ;n = 102
maximum multipoint nonparametric linkage [NPL]
1.99, ). Weak evidence for linkage with hetero-P = .03
geneity within this subset was also observed (HLOD
1.21, ), with ∼20% of families linked. AlthoughP = .02
not statistically significant, suggestive evidence for link-
age to PCAP was observed for the families ( ) thatn = 21
met the three criteria of male-to-male transmission, av-
erage age of diagnosis !66 years, and 5 affected in-
dividuals (maximum multipoint NPL 1.45, ).P = .08
There was no evidence for linkage to CAPB in the brain
cancer–prostate cancer subset. These results strengthen
the argument that prostate cancer is a heterogeneous
disease and that multiple genetic and environmental fac-
tors may be important for its etiology.
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Introduction
Prostate cancer (MIM 176807) is one of the most com-
mon human cancers, occurring in as many as 15% of
men in the United States (Kosary et al. 1995). Although
the majority of cases of prostate cancer are sporadic, it
has long been recognized that familial clustering exists,
with an increased relative risk occurring in relatives of
affected men (Woolf 1960; Cannon et al. 1982; Meikle
and Stanish 1982; Carter et al. 1990; Steinberg et al.
1990; Spitz et al. 1991; Goldgar et al. 1994;Whittemore
et al. 1995). Segregation analysis of prostate cancer sug-
gests the presence of at least 1 dominant susceptibility
locus that may account for up to 10% of all prostate
cancers (Carter et al. 1992; Schaid et al. 1998). Although
genetic linkage analysis is a powerful technique for the
identification of disease susceptibility loci, it is con-
founded by several factors in prostate cancer families.
These factors include a late age of onset, a high phe-
nocopy rate, and a lack of distinguishing features be-
tween the hereditary and sporadic forms of the disease.
In spite of these complications, three presumed pros-
tate cancer susceptibility loci, as well as a rare prostate
cancer–brain cancer susceptibility locus, have been
mapped through linkage studies of high-risk prostate
cancer families. Starting with a genomewide linkage
screen on prostate cancer families with at least three
affected first-degree relatives, Smith et al. (1996)mapped
a locus for hereditary prostate cancer (HPC1 [MIM
601518]) to chromosome 1q24-25. The evidence for
linkage to HPC1 was provided mostly by large pedigrees
(more than five affected) with an early age of diagnosis
(65 years [Gronberg et al. 1997a]). Subsequently, Ber-
thon et al. (1998) localized a second susceptibility locus,
PCAP (HPC2 [MIM 602759]), distal to HPC1 at
1q42.2-43. A third locus, HPCX (MIM 300147), at
Xq27-28 (Xu et al. 1998) was reported in a combined
study with a total of 360 families. More recently, evi-
dence for a prostate cancer–brain cancer susceptibility
locus, CAPB at 1p36 (MIM 603688), was reported by
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Gibbs et al. (1999b), who used linkage studies in high-
risk prostate cancer families with at least one family
member with primary brain cancer.
Several confirmation studies of the HPC1 locus have
been reported, with varying results. Using nonparame-
tric methods, two groups (Cooney et al. 1997; Hsieh et
al. 1997) confirmed linkage in their prostate cancer fam-
ilies to chromosome 1q24-25. However, the evidence in
both of these studies was weak. Three other studies
(McIndoe et al. 1997; Berthon et al. 1998; Eeles et al.
1998) found no evidence of linkage to this locus by use
of both parametric and nonparametric methods. Neither
of two recent confirmation studies of the PCAP (HPC2)
locus found evidence for linkage with use of either par-
ametric or nonparametric methods (Gibbs et al. 1999a;
Whittemore et al. 1999).
Current data regarding the genetics of hereditary pros-
tate cancer suggests that multiple susceptibility genes are
involved and that phenotypic expression is highly var-
iable. In an endeavor to confirm the reported linkage to
the various chromosome 1 regions, we conducted link-
age studies on 144 prostate cancer families by using
microsatellite markers in the regions of 1q24-25 (HPC1)
and 1q42.2-43 (PCAP). Additionally, we examined the
1p36 (CAPB) region for linkage in 13 prostate cancer
families that also contained at least one case of brain
cancer.
Methods
Family Ascertainment
All men who received a radical prostatectomy for clin-
ically localized prostate cancer in the Department of
Urology, or who received radiation therapy in the Di-
vision of Radiation Oncology at the Mayo Clinic (Roch-
ester, MN), were sent a family cancer history survey
(Schaid et al. 1998). A total of 12,675 surveys were sent
on two separate occasions: March 1995 and July 1997.
On the basis of family history, 196 families were iden-
tified for further follow-up. More detailed family his-
tories were obtained over the telephone, and three- to
four-generation pedigrees were constructed. From this
group, a total of 144 families having a minimum of three
men affected with prostate cancer were collected for
linkage studies. For 72 of the families, blood was col-
lected from as many family members as possible, in-
cluding a minimum of three living affected men. For the
remaining 72 families that met the selection criteria,
blood was collected only on affected sib pairs, because
the other affected family members were deceased. All
men who contributed a blood specimen and who had
prostate cancer had their cancers verified by review of
medical records, particularly pathology reports.Wewere
unable to review medical records for deceased individ-
uals. The average age of diagnosis was 66.5 years (range,
54–77 years), with 67 pedigrees having an average age
of diagnosis !66 years. There were 47 pedigrees with at
least five affected men. The average number of affected
men per pedigree was 4.2 (range, 3–11), the average
number of affected men with blood specimens per ped-
igree was 2.7 (range, 2–7), and the average number of
total blood specimens per pedigree was 3.4 (range,
2–12).
A subset of families was identified that contained at
least one case of brain cancer in the pedigree. Although
an effort was made to determine whether the brain can-
cer was a primary tumor versus a metastasis, this was
not possible in all cases. The pedigrees that contained
known metastatic brain cancer were excluded. This re-
sulted in 11 families from the 144 pedigrees described
earlier, plus two additional pedigrees that were obtained
subsequently, resulting in a total of 13 prostate can-
cer–brain cancer families.
The research protocol and informed consent forms
were approved by the Institutional Review Board at the
Mayo Clinic. DNA was isolated from peripheral blood
lymphocytes by use of standard methods.
Genotyping
For the HPC1 locus (1q24-25), linkage analysis was
done with six polymorphic microsatellite markers:
D1S452, D1S212, D1S466, D1S158, D1S422, and
D1S413 (Genome Database). For the PCAP (HPC2)
locus (1q42.2-43), linkage analysis was done with six
additional markers: D1S235, D1S2678, D1S2785,
D1S2842, D1S2850, and D1S321. Four markers,
D1S1597, D1S402, D1S407, and D1S507, mapping to
the CPAB region (1p36) were used for linkage analysis
on the subset of 13 families with at least one case of
brain cancer.
Forward primers were labeled with phosphoramidite
dyes. Each 15-ml reaction contained 25 ng of genomic
DNA, 200 mM dNTPs, 8 mM each primer, 0.5 U
AmpliTaq Gold (PE Biosystems), and 1.5–2.5 mM
MgCl2. Reactions were cycled in either a PE Biosystems
GeneAmp PCR System 9600 or an MJS Tetrad Cycler
as follows: 10 min at 95C, then 35 cycles of 30 s at
95C, 30 s at 58C or 55C, 30 s at 72C; followed by
an extension step of 10 min at 72C. PCR reactions were
held at 5C until analysis. The PCR products were re-
solved on a 5% denaturing polyacrylamide gel and de-
tected by use of an ABI 377 DNA sequencer. Genotypes
were analyzed by use of ABI Genescan 2.1 and ABI
Genotyper 2.0.
Berry et al.: Linkage Analysis in Prostate Cancer 541
Table 1
Two-Point LOD Scores for Model A
MARKER
INTERMARKER
DISTANCE
(cM)
LOD SCORE AT RECOMBINATION FRACTION =
0 .01 .05 .1 .2 .3 .4
HPC1 (n = 144):
D1S452 42.21 29.55 14.13 7.1 1.76 .24 .02
D1S212 5.5 53.04 38.22 19.67 10.65 3.2 .69 .02
D1S466 5.1 33.43 24.05 12.22 6.57 1.97 .46 .06
D1S158 2.4 68.9 48.44 24.14 13.08 4.22 1.16 .2
D1S422 4.4 42.41 31.06 16.18 9.06 3.12 .94 .16
D1S413 4.9 25.4 17.35 7.44 3.04 .07 .4 .18
PCAP (n = 144):
D1S235 51.75 39.28 22.44 13.68 5.54 1.97 .43
D1S2678 1.6 38 29.29 17.09 10.53 4.29 1.52 .33
D1S2850 0 39.55 29.21 15.47 8.73 3.05 .94 .18
D1S2785 9.4 64.9 46.75 24.67 14.21 5.23 1.7 .34
D1S321 2.3 18.94 14.15 7.64 4.27 1.34 .31 .03
D1S2842 5.3 50 36.82 19.44 10.75 3.49 .94 .15
CAPB (n = 13):
D1S1597 4.41 3.24 1.7 .97 .36 .12 .03
D1S402 1.19 9.9 6.95 3.36 1.73 .45 .05 .03
D1S407 2.73 2.71 2.17 1.41 .94 .43 .16 .03
D1S507 .1 5.25 3.73 1.82 .83 .06 .12 .09
NOTE.—Scores for model B were consistent in terms of conclusions but tended to be less extreme than
those for model A for both negative and positive LOD scores (see text).
Linkage Analysis
We performed genetic linkage analyses by both par-
ametric and model-free methods. The parametric two-
point LOD scores were computed by the LINKAGE
package (FASTLINK) by use of an assumed prostate
cancer susceptibility allele frequency of .003 and an au-
tosomal-dominant model. We performed two different
analyses using two different models of age-dependent
penetrances. Model A is essentially the same as that used
by Smith et al. (1996) in the first reported linkage finding
for hereditary prostate cancer. In brief, model A assumed
a 15% phenocopy rate; affected men had penetrances
of .001 and 1.0 for noncarriers and carriers, respectively;
the lifetime penetrances for unaffected men at age 75
years were 16% for noncarriers and 63% for carriers;
and unaffected men at age !75 years and all women
were not informative (i.e., unknown phenotype). Model
B was more refined, with 11 age-dependent liability clas-
ses based on published segregation models (Carter et al.
1992) and SEER data, as implemented by Xu et al. (in
press). Linkage in the presence of heterogeneity was as-
sessed by use of Smith’s admixture test for heterogeneity
(HOMOG program). Multipoint LOD scores were com-
puted with the GENEHUNTER program. Because the
inheritance of prostate cancer is complex, we also per-
formed multipoint identical-by-descent model–free link-
age analyses for affected pedigree members by use of the
Z-all statistic in the GENEHUNTER program. Allele
frequencies were estimated from the data set.
Results
HPC1 (1q24-25) Locus
The parametric two-point LOD scores (model A) for
the six markers in the HPC1 region are shown in table
1. There was no significant evidence of linkage for the
entire data set with either model A or model B. The
maximum cumulative two-point LOD score was 0.40 at
a recombination fraction of .3 for D1S413 with model
A. By using model B, we found that the peak LOD score
was 0.23 at a recombination fraction of .2 for this same
marker. The maximum multipoint LOD score was
40.54 for model A and 1.77 for model B. Generally,
results from models A and B were consistent throughout
all analyses, with model B results being less extreme (i.e.,
LOD scores closer to 0). When Smith’s admixture test
(HOMOG) was used, there was no evidence for linkage
and heterogeneity with either model. However, there
were three families with maximum multipoint LOD
scores 11 (model A), indicating that a few of the families
may be linked to the HPC1 region (on the basis of sim-
ulations under the null hypothesis, less than one family
would be expected to have a LOD score 11). The non-
parametric methods also failed to show, in our data set,
significant evidence of linkage to the HPC1 locus with
a maximum multipoint nonparametric linkage (NPL)
score 0.73 ( ; fig. 1).P = .23
Families were stratified by the presence ( ) orn = 102
absence ( ) of male-to-male transmission, averagen = 42
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Figure 1 Multipoint NPL scores for the whole data set ( ) and four subsets, on a six-marker map of the HPC1 region. The subsetsn = 144
are average age of diagnosis !66 years ( ), at least five affected individuals ( ), male-to-male transmission ( ), and a combinationn = 67 n = 47 n = 102
( ) of !66 years, at least five affected, and male-to-male transmission.n = 21
age at diagnosis (!66 years, , vs. 66 years,n = 67 n =
), and number of affected individuals (fewer than five,77
, vs. at least five, ) and then reexamined forn = 97 n = 47
linkage. The subset of pedigrees that showed male-to-
male transmission, consistent with autosomal inheri-
tance, had a maximum multipoint NPL score of 1.99
( ) at D1S212. Using parametric analysis, we didP = .03
not detect any evidence for linkage when homogeneity
was assumed, but there was weak evidence for linkage
after allowing for heterogeneity (HLOD score 1.21,
). If we assume heterogeneity, an estimated 20%P = .02
of the male-to-male transmission families may show
linkage to the HPC1 region. The subset of families
( ) that met all three criteria (the presence of male-n = 21
to-male transmission, average age at diagnosis !66
years, and at least five affected individuals) had a peak
multipoint NPL score of 1.26 ( ). In addition, ev-P = .11
idence for linkage and heterogeneity in this subset was
observed with an HLOD score of 1.39 ( ), withP = .01
∼44% of these families linked. Stratification by average
age of diagnosis did not result in significantly increased
LOD scores for any of the HPC1 markers. When strat-
ified by number of affected individuals per family, amax-
imum multipoint NPL score of 1.14 ( ) at markerP = .13
D1S452 was attained for the subset of families with at
least five affected individuals. Figure 1 shows the mul-
tipoint NPL graphs for the various subsets.
PCAP (HPC2 [1q42.2-43]) Locus
The studies on the PCAP locus also failed to show
evidence for linkage for the entire data set. There were
no positive cumulative two-point LOD scores with use
of either model (table 1), nor was there evidence for
heterogeneity by use of HOMOG. The multipoint LOD
scores were negative for both models, with a maximum
of 53.33 for model A and 5.16 for model B. Non-
parametric methods also failed to show evidence of link-
age for the whole group, with a maximum NPL score
of 0.76 ( ; fig. 2).P = .78
When stratified, data for the 21 families that met all
three criteria (the presence of male-to-male transmission,
average age at diagnosis !66 years, and at least five
affected individuals) had a peak multipoint NPL score
of 1.45 ( ). Stratification of the families by age ofP = .08
diagnosis did not result in higher LOD scores for the
PCAP locus. Positive, but not significant, multipoint
NPL scores (maximum 0.34, ) were observed inP = .36
the group of 47 families with at least five affected mem-
bers. When stratified by the occurrence of brain cancer,
the families with at least one case of brain cancer had
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Figure 2 Multipoint NPL scores for the whole data set ( ) and for four subsets, on a six-marker map of the PCAP region. Then = 144
subsets are average age of diagnosis !66 years ( ), at least five affected individuals ( ), male-to-male transmission ( ), and an = 67 n = 47 n = 102
combination ( ) of !66 years, at least five affected, and male-to-male transmission.n = 21
a multipoint NPL score of 1.29 ( ) at D1S2785.P = .10
The multipoint NPL graphs for the PCAP region for
these various subsets are shown in figure 2.
CAPB (1p36) Locus
For the 13 families with prostate cancer and brain
cancer, there was no evidence of linkage to the 1p36
locus by use of either parametric or nonparametricmeth-
ods. The two-point LOD scores (model A) for each
marker are shown in table 1. The multipoint LOD scores
were all negative for both models (model A maximum
8.35, model B maximum0.35). The multipoint NPL
scores were also negative for the full group, with a max-
imum of 1.08 ( ; fig. 3).P = .88
Discussion
In the present study, no significant evidence for linkage
of familial prostate cancer to HPC1 (1q24-25) was ob-
served for the whole data set. There may be several rea-
sons for this: disease locus heterogeneity or the use of
incorrect analysis models, both of which diminish sta-
tistical power. It may be that a small fraction of families
are linked to HPC1 but were not detected because of
low statistical power. That this might be the case is sup-
ported by the results of a meta-analysis of 772 families
for linkage to the HPC1 region (Xu et al., in press). This
analysis revealed that the proportion of families linked
to the HPC1 locus is likely to be considerably less (as
low as 6%) than the 34% originally reported. Also, the
current study contained a relatively small number of
pedigrees that appear to provide the greatest evidence
of linkage to HPC1 (Gronberg et al. 1997a, 1997b; Xu
et al., in press): large pedigrees (at least five affected
sampled in two generations) with an early age of onset
(mean !66 years) and male-to-male transmission. There
were three families in our study that had multipoint
LOD scores 1 in the HPC1 region, although only two
of these satisfied all three criteria.
When the data set was stratified into several groups,
however, the subset with male-to-male transmission
showed weak evidence for linkage to HPC1, with a max-
imum NPL score of 1.99 ( ). This is consistentP = .03
with the meta-analysis for linkage to the HPC1 region
that also showed the strongest evidence for linkage in
the male-to-male–transmission families (Xu et al., in
press). Evidence for linkage to HPC1 in the subset of
families with male-to-male transmission was not ob-
served by use of parametric methods with homogeneity,
although models that allowed for heterogeneity did
show some evidence for linkage in this subset, with an
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Figure 3 Multipoint NPL scores for the brain cancer–prostate cancer subset ( ) on a 4-marker map of the CAPB regionn = 13
estimated 20% of families linked. However, the estimate
of the proportion of families linked may be incorrect
because the true model is unknown. Of interest, the only
two confirmatory studies that have supported linkage of
familial prostate cancer to the HPC1 locus have done
so by use of nonparametric methods similar to those
used in this study (Cooney et al. 1997; Hsieh et al. 1997).
Our two-point LOD score results for the parametric
models A and B were consistent in terms of conclusions,
but model B results tended to be less extreme than those
of model A for both negative and positive LOD scores.
The biggest discrepancy was between the multipoint
LOD scores and the multipoint NPL statistic. It is well
known that parametric multipoint LOD scores tend to
be spuriously negative when the parameters used for
analysis (e.g., allele frequency, mode of inheritance, pen-
etrance) are not correct (Risch and Giuiffra 1992). This
is because nonrecombinant offspring tend to be mis-
classified as double recombinants, a rare event, resulting
in the disease locus being “pushed off” the multipoint
marker map. In contrast, the parametric two-point anal-
yses tend to be more robust to model misspecification.
The NPL statistic is ideal for complex traits (Ott 1996).
The advantage of the NPL statistic is that it is not based
on unknown, yet assumed, genetic models, but rather
on the comparison of the observed versus expected shar-
ing of chromosomal regions identical by descent among
affected relatives. For these reasons, we have relied on
the parametric two-point LOD scores and themultipoint
NPL statistics for our main conclusions.
We observed no significant evidence of linkage to
PCAP (HPC2 [1q42.2-43]) for the entire data set, with
either parametric or model-free analyses. Neither this
study nor that of Gibbs et al. (1999a) has confirmed
linkage to the 1q42.2-43 (PCAP) locus. Therefore, the
proportion of families linked to this locus is likely to be
considerably !50%, as was estimated by Berthon et al.
(1998) in the original report. We did find suggestive
evidence for linkage to the PCAP region (maximumNPL
score 1.45; ) in the subset of families that satisfiedP = .08
all three criteria of male-to-male transmission, large size
(at least five affected sampled in two generations), and
early age of onset (mean !66 years). Gibbs et al. (1999a)
also found suggestive, but not significant, evidence for
linkage in their subset of families with at least five af-
fected individuals (maximum NPL score 1.2, ).P = .1
There were 13 families with both prostate cancer and
brain cancer present. However, there was no evidence
for linkage to CAPB (1p36) in this subset. Of interest is
the observation that the prostate cancer–brain cancer
subset had multipoint NPL scores suggestive of linkage
to the PCAP region, which may imply that a general
tumor-suppressor gene is involved in this region. How-
ever, although the known cases of brain metastases were
excluded, not all of the remaining cases were confirmed
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to be primary brain tumors. Therefore, these results are
not definitive.
It is well recognized that familial prostate cancer is
heterogeneous and that several loci, as well as possibly
other genetic and environmental factors, are very likely
to play a role in its etiology. The heterogeneity of this
disease is underscored by our data set, which failed to
show linkage at two of the chromosome 1 loci but did
show linkage to the Xq27-28 region (with stronger ev-
idence in a combined data set) with an estimated 16%
of families linked (Xu et al. 1998). Also, a subset of our
families showed weak evidence of linkage to the HPC1
region. Population differences reflecting different in-
volved loci may further contribute to the heterogeneity
of this disease. For example, two black pedigrees dem-
onstrated positive LOD scores in the original HPC1 re-
port (Smith et al. 1996). The present study population
was entirely white, with one Hispanic and no black fam-
ilies. Other studies failing to report linkage to the HPC1
locus also tended to be less diverse. However, the two
studies (Cooney et al. 1997; Hsieh et al. 1997) that sup-
ported linkage to the HPC1 locus had more ethnically
diverse study populations, which included 6/59 and 6/
79 black families, respectively.
In conclusion, our results suggest that a small subset
of families, characterized by male-to-male transmission,
may be linked to the HPC1 region. In addition, these
results strengthen the argument that prostate cancer is
a complex, heterogeneous disease with multiple genes
and factors contributing to its development. Future
meta-analyses of the PCAP and CAPB regions, as well
as regions identified in the future, will be necessary to
gain an accurate estimate of their involvement in familial
prostate cancer.
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